Source-grounded facts extracted from 10x Genomics, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
10x Genomics, Inc. shareholders approved Non-binding advisory vote to approve executive compensation of named executive officers at the 2026-06-04 meeting.
“Votes For Votes Against Abstentions Broker Non-Votes 176,677,540 2,828,730 748,296 18,560,952”
10x Genomics, Inc. shareholders approved Ratification of appointment of Ernst & Young LLP as independent registered public accounting firm for fiscal year ending December 31, 2026 at the 2026-06-04 meeting.
“Votes For Votes Against Abstentions Broker Non-Votes 197,719,939 458,231 637,346 —”
10x Genomics, Inc. shareholders approved Election of three Class I directors at the 2026-06-04 meeting.
“Nominee Votes For Votes Against Abstentions Broker Non-Votes Serge Saxonov 164,137,381 15,559,860 557,329 18,560,948 Benjamin J. Hindson 162,942,766 16,761,532 550,270 18,560,950 John R. Stuelpnagel 155,628,365 24,072,179 554,023 18,560,951”
10x Genomics, Inc. reported the first quarter ended March 31, 2026 results: revenue $150.8 million, net income Net loss was $13.5 million. Guidance reaffirmed.
“Revenue was $150.8 million for the first quarter of 2026, a 3% decrease from the corresponding period of 2025.”
10x Genomics, Inc. announced a restructuring with charges of between $5.5 million and $6.5 million (approximately 8% of the Company’s global workforce).
“On May 6, 2025, to decrease its costs and adjust its organizational structure to align with its strategic priorities, the Company committed to a reduction in force that is expected to result in the termination of approximately 8% of the Company’s global workforce. In connection with the reduction in force, the Company currently estimates it will incur between $5.5 million and $6.5 million of costs consisting primarily of cash severance costs which the Company expects to recognize in the second quarter of 2025 and pay by the end of third quarter of 2025.”
Mathai Mammen resigned as Member of the Board of Directors at 10x Genomics, Inc..
“On October 24, 2024, Mathai Mammen informed the Company of his decision to resign as a member of the Board of Directors”
Adam S. Taich was appointed as Chief Financial Officer at 10x Genomics, Inc..
“On August 8, 2024, the Company announced that Adam S. Taich will be joining the Company as its Chief Financial Officer, effective August 12, 2024, replacing Justin J. McAnear”
Justin J. McAnear resigned as Chief Financial Officer at 10x Genomics, Inc..
“Justin J. McAnear, who on August 6, 2024 notified the Company of his intention to resign and who will continue to provide transition services as an employee of the Company through August 30, 2024.”
Sarah A. Teichmann was appointed as Director at 10x Genomics, Inc..
“On July 10, 2024, upon the recommendation of its Nominating and Corporate Governance Committee, the Board of Directors of 10x Genomics, Inc. (the “Company”) appointed Sarah A. Teichmann to the Board of Directors as a Class II director effective immediately with a term expiring at the Company's 2027 annual meeting of stockholders or until her successor is duly elected and qualified or until her earlier death, resignation, disqualification or removal.”
Alan V. Mateo was appointed as Director at 10x Genomics, Inc..
“appointed Alan V. Mateo to the Board of Directors as a Class II director effective immediately”
10x Genomics, Inc. reported first quarter ended March 31, 2024 results: revenue $141.0 million, net income -$59.9 million. Guidance reaffirmed.
“Revenue was $141.0 million for the first quarter of 2024, a 5% increase from $134.3 million for the corresponding prior year period. Gross margin was 66% for the first quarter of 2024, as compared to 73% for the corresponding prior year period. The decrease in gross margin was primarily due to change in product mix driven by Xenium instruments. Operating expenses were $154.4 million for the first quarter of 2024, a 3% increase from $150.4 million for the corresponding prior year period. This increase was driven by higher legal expenses and costs for facilities and information technology partially offset by lower personnel expenses, including stock-based compensation. Operating loss was $61.5 million for the first quarter of 2024, as compared to $52.0 million for the corresponding prior year period. Operating loss includes $36.1 million of stock-based compensation for the first quarter of 2024, as compared to $42.1 million of stock-based compensation for the corresponding prior year per”
10x Genomics, Inc. reported fourth quarter and full year ended December 31, 2023 results: revenue $184.0 million for the fourth quarter and $618.7 million for the full year of 2023, net income Net loss was $49.0 million for the fourth quarter of 2023, as compared to a net loss of $17.2 million for the correspond. Guidance initiated.
“10x Genomics, Inc. (the “Company”) issued a press release announcing the Company’s financial results for the fourth quarter and full year ended December 31, 2023.”
James Wilbur departed as Chief Commercial Officer at 10x Genomics, Inc..
“On January 15, 2024, Chief Commercial Officer James Wilbur and 10x Genomics, Inc. (the “Company”) entered into a Transition and Separation Agreement (the “Agreement”) pursuant to which Dr. Wilbur will depart the Company on February 1, 2024.”
10x Genomics, Inc. reported the year ended December 31, 2023 results: revenue $618.7 million.
“Revenue of approximately $618.7 million for the year ended December 31, 2023”
10x Genomics, Inc. reported the three months ended December 31, 2023 results: revenue $184.0 million.
“Revenue of approximately $184.0 million for the three months ended December 31, 2023”
10x Genomics, Inc. reported for the third quarter ended September 30, 2023 results: revenue $153.6 million, net income Net loss was $93.0 million. Guidance raised.
“Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today reported financial results for the third quarter ended September 30, 2023. Recent Highlights • Revenue was $153.6 million for the third quarter, a 17% increase over the corresponding period of 2022, driven by Xenium momentum. • Advanced Xenium gene panel strategy, launching new targeted and custom”
10x Genomics, Inc. reported full year 2023 results: revenue $600 million to $620 million. Guidance raised.
“10x Genomics is raising its full year 2023 revenue guidance and now expects revenue in the range of $600 million to $620 million, representing 16% to 20% growth over full year 2022.”
10x Genomics, Inc. reported the second quarter ended June 30, 2023 results: revenue $146.8 million, net income Net loss was $62.4 million. Guidance raised.
“Revenue was $146.8 million for the second quarter of 2023, a 28% increase from $114.6 million for the corresponding prior year period.”
Bryan E. Roberts resigned as Director at 10x Genomics, Inc..
“On July 18, 2023, Bryan E. Roberts informed 10x Genomics, Inc. (the "Company") of his decision to resign as a member of the Board of Directors (the "Board") of the Company, the Audit Committee of the Board and the Compensation Committee of the Board, effective immediately.”
10x Genomics, Inc. shareholders approved Non-binding, Advisory Vote to Approve Executive Compensation of Named Executive Officers at the 2023-06-14 meeting.
“The Company’s stockholders approved, on a non-binding, advisory basis, the compensation of the Company’s named executive officers as described in more detail in the Company's definitive proxy statement filed with the U.S. Securities and Exchange Commission on April 28, 2023.”
10x Genomics, Inc. shareholders approved Ratification of the Appointment of Independent Registered Public Accounting Firm at the 2023-06-14 meeting.
“The Company’s stockholders ratified the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the Company’s fiscal year ending December 31, 2023.”
10x Genomics, Inc. shareholders approved Election of three Class I directors at the 2023-06-14 meeting.
“The Company’s stockholders approved the election of three Class I directors, each to hold office for a three-year term expiring at the Company’s 2026 annual meeting of stockholders or until his respective successor has been duly elected and qualified or until his or her earlier resignation or removal.”
10x Genomics, Inc. reported first quarter ended March 31, 2023 results: revenue $134.3 million, net income $50.7 million. Guidance raised.
“PLEASANTON, Calif. May 3, 2023 – 10x Genomics, Inc. (Nasdaq: TXG) today reported financial results for the first quarter ended March 31, 2023. Recent Highlights • Revenue was $134.3 million for the first quarter, representing a 17% increase over the corresponding period of 2022. • Surpassed 5,000 customer publications using 10x Genomics products, demonstrating the”
10x Genomics, Inc. reported fourth quarter and full year ended December 31, 2022 results: revenue $156.2 million for the fourth quarter and $516.4 million for the full year, net income Net loss was $17.2 million for the fourth quarter...Net loss was $166.0 million for full year 2022. Guidance initiated.
“Inc. (Nasdaq: TXG) today reported financial results for the fourth quarter and full year ended December 31, 2022 and provided outlook for 2023. Recent Highlights • Revenue was $156.2 million for the fourth quarter and $516.4 million for the full year of 2022, representing 9% and 5% increases over the corresponding periods of 2021. • Increased cumulative instruments”
10x Genomics, Inc. reported the third quarter ended September 30, 2022 results: revenue $131.1 million, net income $41.9 million. Guidance reaffirmed.
“Revenue was $131.1 million for the third quarter of 2022, a 5% increase from $125.3 million for the corresponding prior year period. This increase was primarily driven by higher volume of units sold and growth due to new customers, partially offset by unfavorable foreign exchange fluctuations. Gross margin was 77% for the third quarter of 2022, as compared to 80% for the corresponding prior year period. The decrease in gross margin was primarily due to change in product mix with newly introduced products and increased manufacturing and supply chain costs. Operating expenses were $140.7 million for the third quarter of 2022, a 21% increase from $116.7 million for the corresponding prior year period. This increase was driven by higher personnel expenses, including stock-based compensation and restructuring costs, increased costs for facilities and information technology to support operational expansion, and increased costs for laboratory materials and supplies to support research and dev”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.